Sonoma Pharmaceuticals (SNOA) Net Cash Flow Growth (1y) (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 228.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.64% |
| Mar 31, 2026 | -261.00% |
| Dec 31, 2025 | -147.29% |
| Sep 30, 2025 | -139.90% |
| Jun 30, 2025 | -675.44% |
| Mar 31, 2025 | -87.37% |
| Dec 31, 2024 | 496.71% |
| Sep 30, 2024 | 230.10% |
| Jun 30, 2024 | 23.43% |
| Mar 31, 2024 | -6.71% |
| Dec 31, 2023 | 133.70% |
| Sep 30, 2023 | 37.95% |
| Jun 30, 2023 | 81.11% |
| Mar 31, 2023 | 168.80% |
| Dec 31, 2022 | -561.31% |
| Sep 30, 2022 | -139.01% |
| Jun 30, 2022 | -31.20% |
| Mar 31, 2022 | -1.90% |
| Dec 31, 2021 | -84.86% |
| Sep 30, 2021 | 2,623.32% |